Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Colloidal Oatmeal Cream
Colloidal Oatmeal · 1 trial · 1 indication
The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI). A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final calculation ranging from 0-72.
The signs and symptoms of eczema are measured using the Investigator's Global Atopic Dermatitis Assessment (IGADA). An assessment of atopic dermatitis based on a 4 point scale, ranging from 0 (none) and 3 (severe), is used to describe signs and symptoms in 4 designated body regions. Based on the presence or absence of the total number of signs and symptoms, the final rating is categorized as clear, almost clear, mild, moderate, severe, or very severe.
| Arm | Type | Description |
|---|---|---|
| EPI | ACTIVE_COMPARATOR | - |
| NEE | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EpiCeram® Skin Barrier Emulsion | DEVICE | Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed. |
| Colloidal Oatmeal Cream | DRUG | Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed. |
Inclusion Criteria 1. Able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based upon research site personnel's assessment; 2. Caregiver is able and willing to provide written informed consent for the participant to participate in the trial; ...
Colloidal Oatmeal is used for eczema, a skin condition involving dry, itchy skin. It is being developed as a dermatology treatment by Johnson & Johnson, which trades under the ticker JNJ. The product is also known as Colloidal Oatmeal Cream and has been studied in a Phase 3 trial in babies with dry itchy skin.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of Colloidal Oatmeal. The company is studying the product as a dermatological treatment for eczema. It is also referred to as Colloidal Oatmeal Cream.
Colloidal Oatmeal is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The completed study was a randomized, double-blind, active-controlled trial that enrolled 51 participants with eczema in the United States.
Colloidal Oatmeal has been studied in the Phase 3 trial NCT02120833, titled A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin. The trial enrolled 51 participants with eczema in the United States, included males and females from 2 months of age, and has been completed.
Yes, Colloidal Oatmeal Cream is another name for Colloidal Oatmeal. Both names refer to the same Johnson & Johnson product being developed for eczema. The Phase 3 trial NCT02120833 studied a cream used on babies with dry itchy skin.